Geode Capital Management
IBO

Geode Capital Management’s Impact BioMedical IBO Stock Holding History

Geode Capital Management’s Portfolio IBO Stock Details IBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$546K Sell
1,185,163
-7,762
-0.7% -$4.59K ﹤0.01% 3565
2026
Q1 		$716K Buy
1,192,925
+1,118,547
+1,504% +$559K ﹤0.01% 3464
2025
Q4 		$37.6K Buy
74,378
+29,269
+65% +$15.5K ﹤0.01% 4285
2025
Q3 		$30K Sell
45,109
-4,760
-10% -$3K ﹤0.01% 4381
2025
Q2 		$32.3K Buy
49,869
+26,669
+115% +$15K ﹤0.01% 4291
2025
Q1 		$20.2K Buy
23,200
+2,426
+12% +$4.2K ﹤0.01% 4343
2024
Q4 		$30.1K Buy
+20,774
New +$43.1K ﹤0.01% 4325

Other funds holding IBO

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Global Advisers
Vanguard Global Advisers Malvern, Pennsylvania $215B AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
MAC
Mason & Associates (California) Los Angeles, California $619M AUM 29.44% 1-Year Est. Return

Geode Capital Management's IBO Position: Q2 2026 in Review

Geode Capital Management reduced its Impact BioMedical (IBO) stake by 0.65% in Q2 2026, selling an estimated $4.59K and leaving 1,185,163 shares worth $546K. The position accounts for ﹤0.01% of the portfolio, ranked #3565.

Geode Capital Management first reported a position in IBO in Q4 2024 and has held it in 7 quarters since. The position peaked at $716K in Q1 2026. 22 funds tracked by Wall St. Rank hold IBO as of Q2 2026.

  • Geode Capital Management held 1,185,163 shares of Impact BioMedical worth $546K as of Q2 2026.
  • Geode Capital Management sold 7,762 Impact BioMedical shares in Q2 2026, an estimated $4.59K.
  • Impact BioMedical made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3565 holding.
  • Geode Capital Management first reported a position in Impact BioMedical in Q4 2024 and has held it in 7 quarters since.
  • Geode Capital Management's Impact BioMedical position peaked at $716K in Q1 2026.
  • 22 funds tracked by Wall St. Rank held Impact BioMedical as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.